Related Experiment Video

Updated: Mar 31, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K

Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?

Athanasios Fountas1, Leonidas-Nikolaos Diamantopoulos1, Agathocles Tsatsoulis1

  • 1Department of Endocrinology, University of Ioannina, Stavros Niarchos Avenue, 45110, Ioannina, Greece.

Trends in Endocrinology and Metabolism: TEM
|October 24, 2015
PubMed

Insights

Multi-target tyrosine kinase inhibitors (TKIs) show promise in reversing type 1 and type 2 diabetes mellitus by improving beta cell function and insulin sensitivity. These TKIs offer a novel therapeutic strategy for diabetes by targeting key signaling pathways.

Area of Science:

  • Molecular Biology
  • Endocrinology
  • Oncology

Background:

  • Deregulation of protein tyrosine kinase (PTK) activity is linked to various proliferative diseases.
  • Multi-target tyrosine kinase inhibitors (TKIs) are established treatments for malignancies.
  • Recent clinical observations suggest TKIs can reverse type 1 and type 2 diabetes mellitus (T1DM, T2DM).

Purpose of the Study:

  • To explore the mechanisms by which TKIs may reverse T1DM and T2DM.
  • To investigate the potential of targeting PTKs as a novel therapeutic approach for diabetes.

Main Methods:

  • Review of clinical cases reporting diabetes reversal during TKI therapy.
  • Analysis of experimental in vivo and in vitro studies elucidating TKI mechanisms.
  • Focus on specific PTKs: c-Abl, PDGFR, EGFR, and VEGFR2.

Main Results:

  • Inhibition of c-Abl promotes beta cell survival and enhances insulin secretion.
  • Inhibition of PDGFR and EGFR improves systemic insulin sensitivity.
  • VEGFR2 inhibition reduces islet cell inflammation (insulitis).

Conclusions:

  • Targeting multiple PTKs offers a potential novel therapeutic strategy for correcting diabetes pathophysiology.
  • The multifaceted effects of TKIs on beta cells, insulin sensitivity, and inflammation highlight their potential in diabetes management.
Keywords:
EGFRPDGFRVEGFRc-Abldiabetes mellitustyrosine kinase inhibitors

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.4K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
946
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
646
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K